New York State Common Retirement Fund Purchases 3,599 Shares of Acceleron Pharma Inc. (XLRN)

New York State Common Retirement Fund grew its holdings in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) by 11.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,300 shares of the biopharmaceutical company’s stock after buying an additional 3,599 shares during the period. New York State Common Retirement Fund owned 0.09% of Acceleron Pharma worth $1,042,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Acceleron Pharma by 9.0% during the 2nd quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after buying an additional 330,635 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Acceleron Pharma by 9.1% during the 1st quarter. Vanguard Group Inc. now owns 1,912,335 shares of the biopharmaceutical company’s stock valued at $50,619,000 after buying an additional 158,714 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Acceleron Pharma by 46.6% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after buying an additional 534,440 shares in the last quarter. Eagle Asset Management Inc. boosted its holdings in shares of Acceleron Pharma by 6.6% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,256,642 shares of the biopharmaceutical company’s stock valued at $38,189,000 after buying an additional 77,683 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Acceleron Pharma by 9.7% during the 1st quarter. State Street Corp now owns 1,034,625 shares of the biopharmaceutical company’s stock valued at $27,395,000 after buying an additional 91,451 shares in the last quarter. Hedge funds and other institutional investors own 75.85% of the company’s stock.

In related news, SVP John D. Quisel sold 5,113 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $38.42, for a total transaction of $196,441.46. Following the sale, the senior vice president now owns 57,918 shares in the company, valued at approximately $2,225,209.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Christopher Rovaldi sold 14,000 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $537,740.00. Following the sale, the senior vice president now owns 28,232 shares in the company, valued at approximately $1,084,391.12. The disclosure for this sale can be found here. Insiders have sold a total of 53,513 shares of company stock worth $2,055,485 over the last ninety days. Insiders own 3.90% of the company’s stock.

Acceleron Pharma Inc. (NASDAQ:XLRN) opened at $35.09 on Monday. Acceleron Pharma Inc. has a 52 week low of $23.07 and a 52 week high of $41.69.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.55) EPS. sell-side analysts anticipate that Acceleron Pharma Inc. will post -2.67 EPS for the current fiscal year.

Several equities analysts have recently issued reports on XLRN shares. Credit Suisse Group set a $35.00 price target on Acceleron Pharma and gave the stock a “buy” rating in a research report on Saturday, August 5th. HC Wainwright lifted their price target on Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. Cann reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Finally, BidaskClub lowered Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $43.94.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/11/13/new-york-state-common-retirement-fund-acquires-3599-shares-of-acceleron-pharma-inc-xlrn.html.

Acceleron Pharma Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply